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Background: Hand, foot and mouth disease (HFMD) is caused by members of the family Picornaviridae in the
genus Enterovirus. It has been reported that coxsackievirus A6 (CVA6) infections are emerging as a new and major
cause of epidemic HFMD. Sporadic HFMD cases positive for CVA6 were detected in the mainland of China in recent
years. To strengthen the surveillance of CVA6 infections and outbreak control, the clinical diagnosis is urgently
needed to distinguish the CVA6 infection disease from other infections.
Methods: In order to develop a sensitive quantitative real-time RT-PCR assay for rapid detection of CVA6 RNA,
primers and probe were designed to target the VP1 gene segment of CVA6. The conservation of the target
segment was firstly analyzed by bioinformatic technology. The specificity of the real-time RT-PCR was further
confirmed by detecting other related viruses and standard curves were established for the sensitivity evaluation.
The pharyngeal swab samples from the EV71 and CVA16 unrelated HFMD patients were applied for CVA6 detection
through the established method.
Results: Based on the primer–probe set to detect the target VP1 gene segment of CVA6, the quantitative real-time
RT-PCR assay could discriminate CVA6 infection from other resemble viral diseases with a potential detection limit
of 10 viral copies/ml. The specificity of the assay was determined by sequence alignment and experimentally tested
on various related viruses. The standard curve showed that the amplification efficiency of templates with different
concentrations of templates was almost the same (R2 >0.99). Evaluation of the established method with pharyngeal
swabs samples showed good accordance with the results from serology diagnosis.
Conclusion: This study is the first report developing a VP1 gene-based quantitative real-time RT-PCR for rapid,
stable and specific detection of CVA6 virus. The real-time RT-PCR established in this study can be used as a reliable
method for early diagnosis of CVA6 infection.
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Hand, foot, and mouth disease (HFMD) is characterized
by fever and vesicular eruptions on the hands, feet and
mouth. HFMD is caused by members of the family Picor-
naviridae in the genus Enterovirus [1]. In recent years, the
prevalence of HFMD in the Asia-Pacific region, especially* Correspondence: yjzhang@cdc.zj.cn; med_bp@zju.edu.cn
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reproduction in any medium, provided the orin Southeast Asia, has greatly increased. In China, a rapid
expansion of HFMD out-breaks has occurred since 2004
[2]. In 2011, the Chinese Center for Disease Control and
Prevention (China CDC) confirmed 1,619,706 cases in
Mainland China including 509 deaths. Most outbreaks of
HFMD were associated with the coxsackievirus A16
(CVA16) and human enterovirus 71 (EV71); however,
sporadic cases involving other members of the enterovirus
A species have also been reported [3]. During Fall 2008,
an outbreak of HFMD with onychomadesis (nail shed-
ding) as a common feature occurred in Finland. And the
CVA6 was confirmed as the causative agent [4]. In 2010,
an outbreak of CVA6 associated HFMD occurred inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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madesis and desquamation following HFMD [5]. It was
suggested that CVA6 infections may be emerging as a new
and major cause of epidemic HFMD.
To strengthen the surveillance of CVA6 infections and
outbreak control, an effective detection method for the
CVA6 is required. According to the previous studies, the
traditional method requires reference anti-sera and relies
on virus culture. Neutralization tests are still considered to
be the “gold standard” for the identification of the CVA6
[6,7]. Although an indirect immunofluorescence assay
(IFA) improved upon the traditional method and helped
hospital laboratories deal simply with many clinical speci-
mens, sero-diagnosis produced cross-immune responses
with other enteroviruses. The molecular methods that are
based on PCR and sequencing are faster and more accurate
[8,9]. Recently, reverse transcription-PCR (RT-PCR) and
real-time PCR assays have been used for enterovirus detec-
tion [10,11]. But there is still no advanced molecular detec-
tion and identification method for the CVA6 infection.
The purpose of this research is to develop a real-time
PCR method based on the VP1 gene for the detection of
CVA6 virus. The ability to distinguish it accurately from
other members of the Enterovirus genus would be valu-
able. Based on the unique target, real-time RT-PCR
could provide a simple and convenient identification
method for the CVA6 infection.
Materials and methods
Clinical samples and viruses
This study was approved by the ethics committee of
Zhejiang provincial Center for Disease Control and Pre-
vention (CDC), China. With the permission of their par-
ents, a total of 20 pharyngeal swabs were collected from
the children patients with EV71 and CVA16 unrelated
HFMD. The samples were stored in 3–5 ml of preserva-
tion solution (Hanks solution containing 100 U/ml peni-
cillin and 100 μg/ml streptomycin) at −70°C for analysis.
Poliovirus, coxsackievirus, human enterovirus 71, echo-
virus, rotavirus, sapovirus, norovirus, astrovirus and en-
teral adenovirus strains used in this study were all
provided by Zhejiang provincial CDC.
Sequence analysis and designation of primers
VP1 gene sequences from CVA6 virus strains were down-
loaded from GenBank. The Primer Express soft-ware
package (Applied Biosystems, CA, USA) was used for pri-
mer and probe designation. All the primers used in this
study were synthesized by Invitrogen Co. (Invitrogen,
Shanghai, China). The target segment from VP1 gene
which used for CVA6 virus identification was further used
for conservation analysis through BLAT (http://blast.ncbi.
nlm.nih.gov/Blast.cgi) and Mega 4.0 software (Biodesign
Institute, AZ, USA).T-A cloning and sequencing
Genomic RNA of CVA6 virus was extracted by using
the Virus Nucleic Acid Extraction Kit (Roche, Basel,
Switzerland) and then eluted in TE buffer. A High
Fidelity RT-PCR Kit (TaKaRa, Dalian, China) was used to
amplify the target gene segment. According to the pro-
vided standard manipulation, the total volume per PCR
was 50 μl which included 10 pmol of each of the primers
CAF and CAR (Table 1), 25 μl 2× One Step RT-PCR
Buffer III, 1 μl TaKaRa Ex TagHS (5 U/μl), 1 μl Prime-
Script RT Enzyme Mix II, 4 μl total RNA and 17 μl
RNase Free dH2O. The reverse transcription reaction
was performed by incubation at 42°C for 5 min and
terminated by incubation at 95°C for 10 s, then fol-
lowed by 40 cycles of PCR amplification at 95°C for
5 s, 60°C for 34 s. The products were detected in 1.5%
Ethidium Bromide pre-stained agarose gel after electro-
phoresis. In order to obtain the accurate sequence
data, the PCR product was purified and cloned into
the plasmid pMD19-T by using the T-A clone kit
(TaKaRa). The recombinant plasmids (pMD19-T-VP1)
were used for sequencing by Invitrogen Co. DNA
sequences were compared to the National Center for
Biotechnology Information (NCBI) database.
TaqMan Real time RT-PCR reaction
TagMan Real time RT-PCR reaction was performed by
using the One Step PrimeScript RT-PCR Kit (TaKaRa,
Dalian, China). Each reaction mixture consisted of 10
pmol of the primers CAF and CAR, 20 pmol of the probe
CAP (Table 1), and 4 μl of template RNA in a final vol-
ume of 50 μl. According to the instructions, RT-PCR
reactions were performed with the same condition as the
conventional RT-PCR, which was described above. Fluo-
rescence signals were measured every cycle at the end of
the annealing step.
Sensitivity and specificity of real time RT-PCR assays
Instead of using CVA6 genomic nucleic acid, plasmid
pMD19-T-VP1 was applied for the real-time RT-PCR
sensitivity analysis here. DNA templates from tenfold
serial dilutions of pMD19-T-VP1 were analyzed by the
real-time RT-PCR, and the results were used to generate
a standard curve.
In order to evaluate the specificity of the real time
RT-PCR established in this study, genomic nucleic acid
extracts from the poliovirus typeI-III; coxsackievirus A16,
B1, B5, B3; human enterovirus 71; echovirus 6, 30; rota-
virus A; sapovirus; norovirusII; astrovirus and enteral
adenovirus strains were prepared and used as templates.
The positive recombinant plasmid generated previously,
(pMD19-T-VP1) was used as positive control. These
extracts were analyzed in duplicate reactions on an ABI
7500 sequence detection system by the established
Table 1 Nucleotide sequences of the primers and probe used in this study
Primer/probe Sequence (50to 30) genomic position PCR product size (bp)
CAF CAAGCTGCAGAAACGGGAG 2572- 2590 103
CAR GCTCCACACTCGCCTCATT 2656- 2674
CAP FAM-ACCCCGTTTCGATTCATCACACA-BHQ1 2632-2654
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ber of PCR cycles run) indicated that genomic nucleic acid
from the test strains were not detected.Real-time RT-PCR detection of clinical samples
Genomic nucleic acid extracted from all the pharyngeal
swabs samples were used as templates. With the primers
(CAF and CAR) and the TaqMan probe, the real-time
RT-PCR developed in this study was applied for CVA6
identification. The amplification procedure was the same
as described above.Results
Sequence analysis
After acquiring the VP1 gene from the GeneBank, the
sequence of the VP1 gene from Human CVA6 virus
strain Shizuoka 18 (GenBank NO.: AB678778.1) was
subjected to primer design by using Primer Express soft-
ware. The primer and probe sequences were generated
and the target segment was then applied for homology
analysis through blast in NCBI. We found that the se-
quence of the target gene segment was only conserved
present in Human CVA6 virus strains. The similarities of the
target VP1 gene segment sequences from the CVA6 strains
of China (GenBank NO.: JN655887.1, JN655884.1), Japan
(GenBank NO.: AB678778.1, AB649288.1, AB649287.1,
AB649286.1, AB649289.1, AB649291.1), France (GenBank
NO.: HE572937.1, HE572925.1, HE572914.1, HE572913.1,
HE572907.1, HE572939.1, HE572938.1, HE572936.1), Spain
(GenBank NO.: FR797985.1, FR797984.1), UK(GenBankFigure 1 Homology comparison of the target VP1 gene segment seq
target VP1 gene segment sequences from the CVA6 virus strains of China,
result showed the average variability among these sequences was 5.1%.NO.: FJ525951.1) was 93.2-100% (Figure 1A) and the aver-
age variability was 5.1% as calculated by MegAlign pro-
cedure (Figure 1B). The conservation of the target VP1
gene segment sequence of the Human CVA6 virus sug-
gests that it can be a useful marker for the Human
CVA6 virus detection and identification.PCR amplification and TA clone
After PCR amplification using genomic nucleic acid
from Human CVA6 as template, product was visualized
on a 1.5% agarose gel (Figure 2A). According to the size
of the target VP1 gene segment described above, the size
of the amplification product was correct (103 bp). The
results also suggested the specificity of the primers. The
PCR product was purified and cloned into the plasmid
pMD19-T. The generated recombinant plasmid pMD19-
T-VP1 was further confirmed by sequencing. After com-
parison with the reference sequence from human CVA6
strain Shizuoka 18, we observed that the similarity be-
tween them was 95.1% (Figure 2B). Several site muta-
tions have been found in the sequence of the target VP1
gene segment, However, it showed little impact on the pri-
mers conjugation. It also indicated that the sequence of the
target VP1 gene segment from the human CVA6 of differ-
ent areas showed small variability as described above.Sensitivity and specificity of real time RT-PCR assay
Based on the TagMan probe, a Real-time PCR method
has been established for the detection of Human CVA6
virus in pharyngeal swabs samples. In order to estimateuences from different CVA 6 virus strains. A: The similarities of the
Japan, France, Spain and UK were 93.2-100%. B: Phylogenetic analysis
Figure 2 PCR amplification and sequencing. A: M: Marker; 1: Negative control; 2: PCR amplification product of the target VP1 gene segment
from CVA 6 virus using primers CAF and CAR (103 bp). B: Comparison of the amplified sequence of the target VP1 gene segment with the
reference sequence from strain Shizuoka 18 (GenBank NO.: AB678778.1). The similarity between these sequences was 95.1%.
Figure 3 Sensitivity, specificity analysis of the real-time RT-PCR and clinical samples detection. A: Real-time RT-PCR amplification plot of
the CVA6 viral gene segment. A PCR baseline subtractive curve fit view of the data is shown with relative fluorescence units (RFU) plotted against
cycle number. The default setting of 10 times the standard deviation of fluorescence in all wells over the baseline cycles was used to calculate
the threshold cycle or Ct value for a positive reaction (horizontal line). B: Standard curve analysis of the RNA amplification plots with Ct values
plotted against starting copy numbers. Typical amplification plot derived from serial tenfold dilutions of recombinant plasmid pMD19-T-VP1
ranged from 106 to 101 copies/ml (R2 = 0.9993). C: Specificity analysis of the Real time RT-PCR was performed by using the genomic nucleic acid
from poliovirus typeI-III; coxsackievirus A16, B1, B5, B3; human enterovirus 71; echovirus 6, 30; rotavirus A; sapovirus; norovirusII; astrovirus and
enteral adenovirus strains as control. For the primer–probe sets, there were no positive results obtained except the RNA transcripts of the CVA6
virus. D: Clinical samples were identified by the real-time RT-PCR. By using the recombinant plasmid pMD19-T-VP1 as control, RNA transcripts
from eight clinical samples give a typical amplification plot.
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of recombinant plasmid (pMD-19-T-VP1) DNA tem-
plates generated previously were used for standard curve
analysis, each in triplicate. The detection range of the
real-time RT-PCR method was at least from 101 to 106
copies/ml (Figure 3A). And slight variations were seen
in the amplification efficiency among different templates,
which suggested that the rea-time RT-PCR was stable in
detection of the target VP1 gene segment. Data were
then subjected to log-linear analysis to generate a stand-
ard curve for calculation of unknowns (Figure 3B). The
standard curves regularly exhibited high R2 values
(>0.99).
First, GeneBank was explored to find out whether the
primer sequences paired with sequences other than the
target VP1 gene segment from human CVA6, but after
searching through BLAST, no close hits from gene seg-
ment other than the target VP1 gene segments from
human CVA6 virus were found. Then, the specificity of
the established real-time RT-PCR detection system was
tested by using the genomic nucleic acid from other
virus of the same genus or virus which may cause the re-
semble symptoms. Poliovirus typeI-III; coxsackievirus
A16, B1, B5, B3; human enterovirus 71; echovirus 6, 30;
rotavirus A; sapovirus; norovirusII; astrovirus and enteral
adenovirus have been used for specificity evaluation
here, and we found that only the human CVA6 virus
gave CT values over the detection limit after real-time
RT-PCR detection (Figure 3C).
Identification of bacterial strains isolated from clinical
samples
Pharyngeal swabs samples were obtained from the sus-
pected HFMD patients. Twenty samples which were first
discriminated from the human EV71 and CVA16 infec-
tions were further identified by the real-time RT-PCR
developed in this study. By using the recombinant plas-
mid pMD-19-T-VP1 DNA as positive control, real-time
RT-PCR identification results showed that eight samples
gave a positive amplification (Figure 3D). The PCRFigure 4 Confirmation the identification results of clinical
samples. M: Marker; 1–8: The PCR products of the positive clinical
samples; 9–10: Positive control and negative control. The PCR
products were visualized on an agarose gel and confirmed to be in
the correct size (103 bp).products were also visualized on an agarose gel to con-
firm that they were the correct size and sequenced to
confirm their identity (Figure 4). The serum samples of
these patients were collected during the convalescent
period and applied for the IFA tests. The serology diag-
nosis showed the same results as detection by the real-
time RT-PCR (data not shown). This suggested that the
real-time RT-PCR not only takes less time at lower cost
but also provides a precise approach for the virus
identification.
Discussion
Human enteroviruses have more than 90 serotypes,
which cause a wide spectrum of acute febrile diseases
among infants and children. Hand, foot, and mouth dis-
ease; aseptic meningitis; respiratory tract illnesses; her-
pangina and otitis media are all could be caused by the
infection of the human enteroviruses [12]. HFMD has
become an important issue for China now [13]. A rapid
expansion of HFMD outbreaks has occurred since 2004.
People are still mainly concerned with EV71 and
CVA16, however, little is known about the other entero-
virus infections and distributions [14].
It has been reported that Enterovirus CVA6 was a pri-
mary pathogen associated with HFMD during a nation-
wide outbreak in Finland in autumn of 2008 [15]. In
2010, an outbreak of CVA6 associated HFMD occurred
in Taiwan and some patients presented with onycho-
madesis and desquamation following HFMD. HFMD
cases were found positive for CVA6 was also detected in
the mainland of China in recent years. To strengthen
the CVA6 infections surveillance and outbreak control,
useful diagnostic technologies are required in the clinical
laboratories. The molecular methods that depend on
PCR and sequencing are fast and accurate for CVA6
identification, but few associated research has been
found previously.
Real-time RT-PCR is generally accepted as an accurate
and cost-effective method for virus identification. We
set out to design a quantitative real-time RT-PCR assay
to identify and quantify CVA6 virus present in the clin-
ical samples. VP1 gene has been widely used as the tar-
get for enteroviruses identification, which was also used
here [16]. The Primer Express software has been applied
for primer designation. After bioinformatics analysis, we
found the target segment only conserved present in the
CVA6 strains. The similarity among the sequences from
different strains is above 90%. So it is considered to be a
good target for CVA6 virus identification.
The real-time RT-PCR assay for diagnosis of CVA6
virus infection has many advantages over conventional
methods, either for detection limit or specificity. The
standard curve showed that the amplification efficiency
of templates with different concentrations of DNA
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10 copies/ml at least. Specificity investigation of the
real-time qRT-PCR assay revealed that only the tem-
plates of the CVA6 RNA showed a positive detection
results.
Finally, real-time qRT-PCR established in this study
was further applied to identify the HFMD clinical sam-
ples. Interestingly, 40% of the EV71 and CVA16 unre-
lated HFMD clinical samples were identified as CVA6
virus infection. So the CVA6 virus seems to be a primary
pathogen associated with HFMD besides EV71 and
CVA16. Though the majority of HFMD cases are caused
by EV71 and CVA16 infections here in China, when
diagnosis of the HFMD cases shows RT-PCR positive for
enterovirus but negative for EV71 and CVA16, it is ne-
cessary to use the method established here for further
identification.
In conclusion, the real-time RT-PCR assay for CVA6
detection presented in this report provided a reliable
tool for early clinical diagnosis, which will enhance the
diagnostic capacity of epidemiological surveillance and
guide clinical treatment for CVA6 infection.
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